Vitamin C in Atrial Fibrillation Ablation

Completed · Phase 2 · Has a placebo group

Conditions studied: Atrial Fibrillation Ablation

In brief

Single-center, double-blinded, randomized, controlled safety and feasibility pilot study of high dose IV ascorbic acid (200mg/kg) over 24 hours, divided into four doses and administered every six hours with a 30 minute IV infusion time per dose, compared to matched placebo infusion

Key facts

Study ID

NCT03148236

Run by

Virginia Commonwealth University

People needed

20

Starts

2017-09-18

Expected to finish

2018-03-13

Last updated by the study team

2019-04-16

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age >/= 21 years
• Diagnosis of atrial fibrillation with plans for a catheter-based ablation procedure
• Ability to provide informed consent and willingness to be included in the study

You may not qualify if…

• Known allergy to Vitamin C
• Inability to obtain informed consent
• Diabetes mellitus either requiring the use of insulin therapy or not requiring the use of insulin therapy but which is uncontrolled, defined as a glycosylated hemoglobin of greater than or equal to 8%
• Prior catheter-based ablation for atrial fibrillation
• Pregnancy or breast feeding
• Active renal calculus
• Active acute or chronic infection (including HIV or hepatitis C)
• Active or recent (within 5 years) malignancy
• Autoimmune or autoinflammatory disease
• Recent or active use of immunosuppressive medications
• Non-English speaking
• Ward of the state (inmate, other)

Where it is running

• Virginia Commonwealth University — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.